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Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193 S183days vs. 13.1 days, P < 0.001) in the ID-CY pts, likely because
of higher infused CD34+ cell dose. Rate of adverse events
were higher in the ID-CY cohort including neutropenic fevers
(p¼0.02), intravenous antibiotic use (p¼0.03), hospitaliza-
tion (p¼0.05) and packed red cell transfusions (p¼0.007).
Conclusion: In the era of novel agents compared to P, ID-CY
produced a more robust PBPC mobilization, faster engraft-
ment, but was associated with signiﬁcantly higher (but
manageable) toxicity, and no difference in mobilization
failure rates. These data support use of either intermediate
dose - cyclophosphamide or plerixafor-based PBPC mobili-
zation in MM pts undergoing stem cell collection following
novel induction therapies.Figure 1. Log-HCMI decay curve: (A) Representative NHL patient from cluster
1; (B) Representative MM patient from cluster 2; (C) Representative NHL
patient from cluster 3.137
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Hematopoietic cell (HC) mobilization to support high dose
therapy is generally carried out using cytokines with or
without chemotherapy. The resulting HC yield and the
duration of cell collection have beenwell studied and tend to
be variable. No consistent unifying relationship has been
described which would reliably represent the kinetics of this
process between different patients. To accomplish this, the
HC yield from the mobilization procedures for 431 patients
was examined. The diagnoses were multiple myeloma
(N¼220), non-Hodgkin's lymphoma (155) and Hodgkin's
lymphoma (56). Mobilizing regimens included chemo-
therapy + GCSF (97), GCSF (232), GCSF + plerixafor (84). To
normalize the HC yield between patients, the total number of
CD34+ cells collected on a given day was divided by the
volume of blood (L) processed and was termed the HC
mobilization index (HCMI). For the combined cohort the
mean HCMI value on day 1 of apheresis (HCMI1) was 19.7
( 38.9)  106 CD34+ cells/L/day. A signiﬁcant correlation
was found between HCMI1 and the circulating CD34+ cell
count on day 1 (R2 0.69, P < 0.01), and the total HC yield in
each patient (0.97, P < 0.01). These observations were
consistent in patients with various diagnoses and receiving
different mobilizing regimens. Daily HCMI values were
plotted over days of apheresis to determine the rate of
change. A general trend of declining HCMI values over days
of apheresis was observed, with some patients showing an
initial increase. To offset the effect of the large range of HCMI
values observed, the logarithm (log) of HCMI for each day
was plotted against day of apheresis for each patient with>2
days of collection (n¼279) to give individual log-HCMI decay
curves. A quadratic equation (y¼ax2+bx+c) provided the best
ﬁt for these curves (mean R2 0.88), demonstrating a parabolic
relationship such that log HCMI increased and declined in
proportion to square of time (in days) following the start of
apheresis. It was noted that the values of coefﬁcients were
normally distributed in the study population; coefﬁcient
a (mean, -0.04  0.2), b (0.04  1.1), and c (1.7  1.2). A Two-
step cluster analysis of these coefﬁcients distinguished three
main groups (clusters) of patients. Patients in cluster 1 (38%)
tended to have an initial increase in HCMI followed by an
asymptotic decline; those in clusters 2 (50.2%) and 3 (8.6%)
displayed declines of varying magnitude. Cluster 1 showed
a higher proportion of NHL patients (p¼0.01), whereas MM
was over-represented in cluster 2 (p¼0.008), consistent withthe notion that prior chemotherapy received by NHL patients
impacted their mobilization kinetics. In conclusion, we
demonstrate that HC yield during various mobilization
procedures follows mathematically predictable kinetics
which may reﬂect underlying hematopoietic reserve.138
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Background: High-dose chemotherapy and autologous
hematopoietic stem cell transplantation (auto-HCT) is an
effective treatment for systemic light chain amyloidosis (AL).
Fluid retention and weight gain during peripheral blood
hematopoietic stem cell (PBSC) mobilization with growth
Abstracts / Biol Blood Marrow Transplant 19 (2013) S178eS193S184factors like ﬁlgrastim is a predictor of poor outcome after
auto-HCT for AL. (Leung N et al. Blood 2005;106:3353-3357)
Methods: We performed a retrospective chart review to
identify patients with excessive weight gain while under-
going ﬁlgrastim-induced PBSC mobilization. The primary
endpointwas todetermine the incidence of> 2% bodyweight
gain during PBSC mobilization. Secondary endpoints were to
identify the factors that predict abnormal weight gain and to
evaluate its impact on NRM and OS after auto-HCT.
Results: We identiﬁed 95 patients with AL who underwent
PBSC mobilization and collection followed by auto-HCT
between 2002 and 2011. Thirty-nine (41%) patients had renal
involvement, 12 patients had cardiac involvement (12.6%)
and 5 (5.2%) patients had liver involvement. Seven patients
required hospitalization during PBSC mobilization due to
ﬂuid overload. Six patients died within a year of auto-HCT
non-relapse causes with 1-year NRM of 6.3%. Median follow
up after auto-HCT in surviving patients was 13 months.
Kaplan-Meier estimates of median OS was 73 months. Forty-
nine (51.5%) patients had >2% weight gain due to ﬂuid
overload during PBSCmobilization, while 46 patients (48.5%)
had 2 % weight gain. More patients with >2% weight gain
required diuretics (34 vs. 10: P < .0001) and had lower
median serum albumin (2.8 vs. 3.75 g/dl, P < 0.0001). There
were no signiﬁcant differences in baseline serum creatinine,
GFR, alkaline phosphatase, ﬁlgrastim dose, urine total
protein, BNP, ejection fraction, cardiac septal thickness,
number of organs involved, or cardiac or renal involvement
between the two groups. 1-year NRM was 6.1 vs. 8.6 % in
patients with >2% or 2% weight gain (p¼0.70). There was
no signiﬁcant difference in median OS survival between
patients with > or 2% weight gain (p¼0.54: Figure 1).
Conclusion: Patients with AL and low baseline serum
albumin are at higher risk of ﬂuid retention and excessive
weight gain that may require hospitalization. However, in
our study, this weight gain did not have an adverse impact on
NRM or OS.Figure 1.139
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The aim of this case report is to describe the use of plerixafor
in a patient with multiple myeloma and dialysis-dependantrenal failure. A 43-year-old man with multiple myeloma and
dialysis-dependent renal failure was evaluated for an autol-
ogous stem cell transplant (ASCT). Following Stem cell
mobilisation with cyclophosphamide 1.5g/m2 and 9 doses of
granulocyte colony-stimulating factor (G-CSF) 10mcg/kg/day
the patient's pre apheresis CD34+ count was inadequate at
2.18 cells/mL. Perixafor was prescribed to achieve stem cell
mobilisation. There is no dose recommendation for plerixafor
in patients with CrCl< 20mL/min or those on dialysis. In this
patient we used 0.16mg/kg/day dose, which is the dose rec-
ommended for patients with CrCl 20-50mL/min. The ﬁrst
plerixafor dose was given subcutaneously post-dialysis 8
hours before apheresis and the second dose was given the
next day 9 hours prior to second apheresis session. The pre-
apheresis CD34+ countwas 11.99 and8.82 cells/mLwith a total
White cell count of 22.2 and 17.3 x 10^9/L after the ﬁrst and
second doses respectively. The patient underwent stem cell
collectionvia the SpectraOptia cell separatorwith a total yield
of 2.4 x 106 cells/kg. There were no observed toxicities with
plerixafor. InMay 2012, 6weeks after stem cell collection, the
patient underwent ASCT with reduced dose of Melphalan
140mg/m2. Neutrophil engraftment occurred at day +11, the
patientwasdischarged at day+16. Todate thepatient remains
well and in remission. This case report illustrates that pler-
ixafor can safely and effectively be used to mobilise adequate
stem cells in multiple myeloma patients with end stage renal
failure. Information regarding dosing and safety of plerixafor
in dialysis patients remains limited,wehope that information
provided by this report would be useful for other clinicians
who are considering the use of plerixafor in this setting.141
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Autologous stem cell transplantationplays a critical role in the
management of patients with hematologic malignancies
such as multiple myeloma and malignant lymphoma. The
minimum number of CD34 positive cells required for trans-
plantation is believed to be 2.0106 cells/kg. Up to 20% of the
patients, however, fail to reach the number after a single
collection attempt and require multiple aphereses to obtain
a sufﬁcient number of stem cells. To predict the outcome of
mobilization, several pre-mobilization factors have been
investigated, including peripheral blood CD34+ cell count at
the time of harvest, but little is as yet known about the
signiﬁcance of serum lactate dehydrogenase (LDH). We,
therefore, sought to evaluate the predictive potential of serum
LDH for the autologous stem cell yield. Peripheral blood stem
cell mobilization attempts were made from April 2002 to
March 2012 for 55 consecutive patients of hematologic
disorders. Primary diagnosis of our patients and their mobi-
lization chemotherapy regimens are shown in Table 1. All
patient received G-CSF (ﬁlgrastim 400mg/sq/day or lenogras-
tim 10mg/kg/day subcutaneously). None was mobilized with
G-CSF alone. Aphereseswere repeated until the total stem cell
yield exceeded 2106cells/kg, for maximum 3 consecutive
days. Forty-four patients successfully produced the sufﬁcient
numberof stemcells,while 11patients failed (poormobilizer).
